Trends in consumption of psychiatric drugs in Serbia and Montenegro 2000–2004

Divac, Nevena; Toševski, Dušica Lečić; Babić, Dragan; Djurić, Dušan; Prostran, Milica; Samardzić, R

doi:10.1002/pds.1316

Cited by 15 publications

(20 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regarding the issue of incomplete data, it is interesting to observe that, for example, our findings on anxiolytic and antipsychotic drug use in Serbia do not support the findings of a previous study that showed a considerably lower consumption of these two drug classes [ 21 ]. This inconsistency may be related to the use of different data sources and providers.…”

Section: Discussioncontrasting

confidence: 99%

The use of driving impairing medicines: a European survey

Ravera

Hummel

Stolk

et al. 2009

Eur J Clin Pharmacol

View full text Add to dashboard Cite

AimTo analyse the consumption of a number of medicines with a known potential for increasing the risk of road traffic accidents in the general population of Europe.MethodsQuestionnaires were distributed through the European Drug Utilization Research Group (EuroDURG) and Post-Innovation Learning through Life-events of drugs (PILLS) networks. A total of 30 countries (the current EU Member States, Iceland, Norway and Switzerland) were asked to supply data on the use of driving impairing medicines for the period 2000–2005, aggregated at the level of the active substance and presented in Defined Daily Doses (DDDs) per 1000 inhabitants per day.ResultsNational utilization data were provided by 12 of the 30 countries. Based on these data, a considerable increase in consumption was only seen for the antidepressants and the selective serotonin reuptake inhibitors. A slight increase, decrease or no increase was seen for the rest of the drugs studied (i.e. opioids, antipsychotics, anxiolytics, hypnotics and sedatives, drugs that are used in addictive disorders and antihistamines). Limitations were encountered when data on driving impairing medicines were compared between countries (e.g. variation in the data sources and providers, population coverage, inclusion of hospital data, use of divergent ATC/DDD versions) and, therefore, a cross-national comparison could not be performed.ConclusionsDuring the study period, trends within countries showed slight to no increase in the consumption of selected medicinal drug groups, with the exception of the antidepressants and the selective serotonin reuptake inhibitors: they showed a remarkable increased use during the study time-frame. Our results illustrate that it is still difficult to perform a valid and comprehensive collection of drug utilization data on driving impairing medicines. Therefore, efforts to harmonize data collection techniques are required and recommended.

show abstract

Section: Discussioncontrasting

confidence: 99%

The use of driving impairing medicines: a European survey

Ravera

Hummel

Stolk

et al. 2009

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…The first episode of depression occurred 9 years prior to the current (2-15 years); the average number of hospitalizations was 2 (1)(2)(3)(4). Patients with the other diagnoses were similar to the unipolar depression group in terms of sociodemographic and clinical parameters (47.6 ± 10.9 years of age, p = 0.07; females 56%, p = 0.11; high school 54.1%, p = 0.96; first diagnosis 8 years prior to the current study (3-16 years), p = 0.70; the number of hospitalizations 2 (1-4), p = 0.10)).…”

Section: Resultsmentioning

confidence: 99%

“…The use of antidepressants (ADs) has been steadily increasing during the last decade 1,2 . Drugs from this group act predominantly on serotonergic and/or noradrenergic transmission and reduce a spectrum of symptoms -from affective and will-instinctive to cognitive psychopathology.…”

Section: Introductionmentioning

confidence: 99%

Factors influencing the choice of antidepressants: A study of antidepressant prescribing practice at University psychiatric clinic in Belgrade

Maric¹,

Stojiljković

Pavlović

et al. 2012

VOJNOSANIT PREGL

View full text Add to dashboard Cite

show abstract

“…3,[5][6]24 Noutros países, as benzodiazepinas mais prescritas são o diazepam (Sérvia e Montenegro, Austrália) e o lorazepam (Canadá). [25][26] Pouco se pode inferir acerca da qualidade da prescrição a nível populacional sem informações sobre o motivo da prescrição e a prevalência da(s) doença(s) as- sociada(s). 15 A codificação de diagnósticos no SAM não ocorre ainda de modo uniforme, pelo que não se pode relacionar a prescrição de fármacos com a prevalência de patologias baseada na codificação.…”

Section: Discussionunclassified